



1047 Elwell Court, Palo Alto  
CA 94303 USA  
Tel (US): +1 (650) 390 9000  
Tel (AU): 1-800-778-662  
Fax: +1 650 390 9007  
[www.airxpanders.com](http://www.airxpanders.com)

19 October 2017

## Quarterly Conference Call and Business Update

**Palo Alto, CA, United States – AirXpanders, Inc. (ASX: AXP)**, a medical device company focused on the design, manufacture, sale and distribution of the AeroForm® Tissue Expander System, will release its Appendix 4C and Quarterly Cash Flow Report on Friday 20 October (AEDT).

Investors are invited to join a conference call on Friday 20 October 2017 9:00am AEDT (Thursday 19 October 3:00pm PDT) hosted by AirXpanders President and CEO Scott Dodson, and CFO/COO Scott Murcray, who will provide a business update on its latest activities over Q3 2017.

To pre-register for the call please follow the link below:

<https://services.choruscall.com.au/diamondpass/AirXpanders-254004-invite.html>

You will receive a calendar notification with dial in details and PIN for fast track access to the call.

- ENDS -

<i><b>Company</b></i>	<i><b>Investor relations</b></i>
Scott Dodson President & CEO Tel: +1 (650)-390-9008 Email: <a href="mailto:sdodson@airxpanders.com">sdodson@airxpanders.com</a>	Kyahn Williamson WE Buchan Tel: +61 (3) 9866 4722 / + 61 (0)401018828 Email: <a href="mailto:kwilliamson@we-buchan.com">kwilliamson@we-buchan.com</a>

### **About AirXpanders**

Founded in 2005, AirXpanders, Inc. ([www.airxpanders.com](http://www.airxpanders.com)) designs, manufactures and markets innovative medical devices to improve breast reconstruction. The Company's AeroForm Tissue Expander System, is used in patients undergoing two-stage breast reconstruction following mastectomy. Headquartered in Palo Alto, California, AirXpanders' vision is to be the global leader in reconstructive surgery products and to become the standard of care in two-stage breast reconstruction. AirXpanders is a publically listed Company on the Australian Securities Exchange under the symbol "AXP." AeroForm was granted U.S. FDA *de novo* marketing authorization in 2016, first CE mark in Europe in 2012 and is currently licensed for sale in Australia.

### **Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, commercial success of our U.S. launch, the success of our sales personnel in on-boarding and training physicians, the clinical benefits to physicians and patients, the ability of our third party contract manufacturer to produce our product in greater capacity and at lower gross margins.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. AirXpanders may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements. For

additional information and considerations regarding the risks faced by AirXpanders that could cause actual results to differ materially, see its most recent Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission on August 9, 2017 including under the caption "Risk Factors," as well as other periodic reports filed with the SEC from time to time. AirXpanders disclaims any obligation to update information contained in any forward-looking statement, except as required by law.

For more information, refer to the Company's website at [www.airxpanders.com](http://www.airxpanders.com).